Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Alexion Pharmaceuticals, Inc. (NASDAQGS: ALXN) breached their fiduciary duties to shareholders. Alexion, a biopharmaceutical company, develops and commercializes life-transforming therapeutic products.

View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/alexion-pharmaceuticals-inc-dec-2016

Alexion's Top Executives Step Down

Alexion disclosed in November 2016 that the company was investigating allegations made by a former employee regarding improper sales practices with respect to its flagship drug, Soliris. Alexion's Chief Executive Officer, David Hallal, and Chief Financial Officer, Vikas Sinha, recently left their roles at the company amid the internal investigation. A Cowen analyst wrote to investors, "We now believe the board lost confidence in its senior leadership team, perhaps due to findings of unprofessional activity that were uncovered during the investigation, and decided that a change needed to be made now." On this news, Alexion's stock fell, closing at $110.01 per share on December 13, 2016. The company, which delayed the filing of its most recent performance report due to the investigation, expects to file it in January.

Alexion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Robbins Arroyo LLP
Darnell R. Donahue
619-525-3990 or Toll Free (800) 350-6003
DDonahue@robbinsarroyo.com
www.robbinsarroyo.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today